Study guide

2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis

Combined Medical Services Examination UPSC CMS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Logistics & Pattern

1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths

2 Chapter 2: General Medicine - Cardiology & Respiratory

2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism

3 Chapter 3: General Medicine - Gastroenterology & Hepatology

3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes

4 Chapter 4: General Medicine - Nephrology & Endocrinology

4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction

5 Chapter 5: General Medicine - Neurology, Haematology & Infection

5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue

6 Chapter 6: General Medicine - Emergency Medicine & Toxicology

6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology

7 Chapter 7: Paediatrics - Neonatology & Child Growth

7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones

8 Chapter 8: Paediatrics - Child Health & Nutrition

8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning

9 Chapter 9: Surgery - General Surgery, Wounds & Shock

9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery

10 Chapter 10: Surgery - Surgical Specialties I

10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi

11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia

11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease

12 Chapter 12: Obstetrics - Antenatal Care & Complications

12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management

13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH

13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care

14 Chapter 14: Gynaecology & Family Planning

14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods

15 Chapter 15: PSM - Epidemiology & Biostatistics

15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing

16 Chapter 16: PSM - Disease Epidemiology & Programmes

16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling

17 Chapter 17: PSM - Health Planning & Environmental Health

17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education

2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis

Key Takeaways Explain This Topic AI

Streptococcus pneumoniae is the most common cause of Community-Acquired Pneumonia (CAP), while atypical pathogens (Mycoplasma, Legionella) present with extrapulmonary symptoms and require macrolides or respiratory fluoroquinolones.

The CURB-65 score stratifies CAP mortality risk (Confusion, Urea >7 mmol/L, Respiratory rate ≥30, BP <90/60, Age ≥65): scores 0-1 are managed outpatient, score 2 inpatient ward, and scores ≥3 require intensive care assessment.

Under India's National Tuberculosis Elimination Program (NTEP), CBNAAT (GeneXpert MTB/RIF) is the mandatory primary diagnostic test for suspected pulmonary TB to confirm M. tuberculosis complex and detect Rifampicin resistance upfront.

Drug-sensitive pulmonary TB is treated with a 6-month regimen (2 months Intensive HRZE + 4 months Continuation HRE), with strict awareness of drug toxicities: Isoniazid (peripheral neuropathy - prevent with Vit B6), Rifampicin (orange secretions), Pyrazinamide (hyperuricemia/hepatotoxicity), and Ethambutol (optic neuritis/color blindness).

Last updated: July 2026

  • Community-Acquired Pneumonia & Pulmonary Tuberculosis
  • 1. Community-Acquired Pneumonia (CAP) Pathophysiology & Etiology

Community-Acquired Pneumonia (CAP) is an acute infection of the pulmonary parenchyma acquired outside of hospital or healthcare facilities.

Etiological Spectrum

Category Causative Pathogens Clinical & Radiologic Features

Typical Bacterial Streptococcus pneumoniae (most common ~50%), Haemophilus influenzae , Moraxella catarrhalis , Staphylococcus aureus Sudden onset high fever, rigors, productive cough with rusty sputum ( S. pneumoniae ), lobar consolidation on chest X-ray.

Atypical Bacterial Mycoplasma pneumoniae , Legionella pneumophila , Chlamydia pneumoniae Insidious onset, dry cough, prominent extrapulmonary symptoms (headache, myalgias, low grade fever). Interstitial / patchy infiltrates ("walking pneumonia").

Viral Influenza A/B, SARS-CoV-2, Respiratory Syncytial Virus (RSV) Diffuse bilateral interstitial infiltrates, prominent systemic flu-like symptoms.

Key Pathogen Associations (UPSC CMS High-Yield)

Klebsiella pneumoniae: Alcoholics, diabetics; presents with "currant jelly" sputum and upper lobe cavitation (bulging fissure sign).

Staphylococcus aureus: Secondary bacterial pneumonia following Influenza virus infection; prone to causing cavitary lesions, pneumatoceles , and empyema.

Mycoplasma pneumoniae: Young adults in dormitories/military camps; associated with erythema multiforme , cold agglutinin autoimmune hemolytic anemia (IgM), and bullous myringitis.

Legionella pneumophila: Exposure to contaminated air conditioning cooling towers or water plumbing; presents with high fever, relative bradycardia (Faget sign) , hyponatremia, diarrhea, and confusion.

2. Risk Stratification: The CURB-65 Score

The CURB-65 criteria predict 30-day mortality and determine the appropriate site of care (Outpatient vs Inpatient Ward vs ICU):

  • Criterion Description Points
  • C Confusion (Abnormal mental status test score ≤ 8 \le 8 ≤ 8 or new disorientation) 1

U Urea (Blood Urea Nitrogen > 19 mg/dL >19 \text{ mg/dL} > 19 mg/dL or Serum Urea > 7 mmol/L >7 \text{ mmol/L} > 7 mmol/L ) 1

R Respiratory Rate ≥ 30 breaths/min \ge 30 \text{ breaths/min} ≥ 30 breaths/min 1

B Blood Pressure (Systolic < 90 mmHg <90 \text{ mmHg} < 90 mmHg OR Diastolic ≤ 60 mmHg \le 60 \text{ mmHg} ≤ 60 mmHg ) 1

  • 65 Age ≥ 65 years \ge 65 \text{ years} ≥ 65 years 1
  • CURB-65 Management Triage

Total Score Mortality Risk Recommended Management Disposition

0 – 1 Low (<3%) Outpatient care with oral antimicrobial therapy.

2 Moderate (9%) Inpatient hospital ward admission or close outpatient monitoring.

≥ 3 \ge 3 ≥ 3 High (15–40%) Severe CAP: Urgent inpatient hospitalization ; evaluate for ICU admission (especially if score 4–5).

3. Empiric Antimicrobial Treatment Protocols

Treatment must be initiated promptly based on setting and national/international guidelines:

Outpatient (Healthy, no comorbidity): Oral Amoxicillin 1 g 1 \text{ g} 1 g tid OR Azithromycin 500 mg 500 \text{ mg} 500 mg day 1 then 250 mg 250 \text{ mg} 250 mg daily OR Doxycycline 100 mg 100 \text{ mg} 100 mg bid.

Outpatient (With Comorbidities - COPD, DM, CKD, heart disease): Oral Amoxicillin/Clavulanate + Macrolide (Azithromycin) OR Monotherapy with Respiratory Fluoroquinolone ( Levofloxacin 750 mg 750 \text{ mg} 750 mg daily or Moxifloxacin 400 mg 400 \text{ mg} 400 mg daily).

Inpatient Non-ICU Ward: IV Beta-lactam ( Ceftriaxone 1 − 2 g 1-2 \text{ g} 1 − 2 g daily or Cefotaxime ) + IV/Oral Macrolide ( Azithromycin ) OR IV Respiratory Fluoroquinolone ( Levofloxacin ).

Inpatient ICU (Severe CAP): IV Beta-lactam ( Ceftriaxone 2 g 2 \text{ g} 2 g daily or Piperacillin-Tazobactam ) + IV Azithromycin OR IV Levofloxacin . Add IV Vancomycin or Linezolid if MRSA is suspected.

4. Pulmonary Tuberculosis (TB) & NTEP Guidelines

Tuberculosis is caused by Mycobacterium tuberculosis , an obligate aerobic, acid-fast bacillus (AFB).

Clinical Manifestations

Constitutional Symptoms: Low-grade fever with characteristic evening rise of temperature , night sweats, anorexia, weight loss.

Pulmonary Symptoms: Chronic cough > 2 weeks >2 \text{ weeks} > 2 weeks , mucopurulent sputum production, hemoptysis, pleuritic chest pain.

Radiology: Primary TB presents with Ghon focus (subpleural parenchymal lesion) + lymphadenopathy = Ghon Complex . Secondary/Reactivation TB demonstrates apical and subapical cavitary lesions in upper lobes (high P O 2 PO_2 P O 2 ​ ).

Diagnostic Cascade (National Tuberculosis Elimination Program - NTEP India)

Under NTEP guidelines, sputum microscopy is replaced by rapid molecular diagnostics as the primary test:

CBNAAT (Cartridge Based Nucleic Acid Amplification Test / GeneXpert MTB/RIF): Mandatory initial diagnostic test for all presumptive TB cases.

Simultaneously detects M. tuberculosis complex DNA and mutations in the rpoB gene conferring Rifampicin resistance within 2 hours.

Sputum Smear Microscopy: Ziehl-Neelsen (ZN) staining or Auramine-O Fluorescent staining (detects acid-fast bacilli; requires ≥ 10 , 000 bacilli/mL \ge 10,000 \text{ bacilli/mL} ≥ 10 , 000 bacilli/mL ).

Line Probe Assay (LPA): Used for rapid second-line drug susceptibility testing (Fluoroquinolones, Injectable drugs).

Liquid Culture (MGIT): Gold standard for confirmation and definitive DST.

5. NTEP Anti-Tubercular Therapy (ATT) Regimens

Treatment of Drug-Microbiologically Sensitive Pulmonary TB consists of Fixed-Dose Combination (FDC) tablets administered daily according to weight bands:

Intensive Phase (IP) - 2 Months (2 HRZE): Daily Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E). Rapidly kills actively dividing bacilli and clears sputum.

Continuation Phase (CP) - 4 Months (4 HRE): Daily Isoniazid (H), Rifampicin (R), Ethambutol (E). Eliminates persistent dormant bacilli to prevent relapse.

NTEP Update Note: Ethambutol is included in the Continuation Phase (4 HRE) under NTEP to protect against monotherapy in cases of undetected primary isoniazid resistance.

6. High-Yield Adverse Effects of First-Line Anti-TB Drugs

Drug Primary Mechanism of Action Major Adverse Effects & Toxicity Profiles Clinical Pearls & Antidotes

Isoniazid (H) Inhibits mycolic acid synthesis Peripheral Neuropathy (due to Vitamin B6 deficiency), Hepatotoxicity , Drug-induced Lupus Co-administer Pyridoxine (Vitamin B6 10-25 mg/day) to prevent neuropathy.

Rifampicin (R) Inhibits bacterial DNA-dependent RNA polymerase Orange-red discoloration of bodily fluids (urine, tears, sweat), Hepatotoxicity , Strong CYP450 inducer, Thrombocytopenia Reassure patient regarding orange secretions. Interacts with oral contraceptives and Warfarin.

Pyrazinamide (Z) Disruption of membrane potential & energy metabolism Hyperuricemia (causes arthralgia/gout), Most Hepatotoxic first-line drug Avoid in severe liver disease or acute gouty arthritis.

Ethambutol (E) Inhibits arabinosyl transferase (cell wall synthesis) Retrobulbar Optic Neuritis (decreased visual acuity, red-green color blindness , central scotoma) Bacteriostatic (others are bactericidal). Test visual acuity & color vision baseline; Contraindicated in young children .

Streptomycin (S) Inhibits 30S ribosomal subunit protein synthesis Ototoxicity (vestibular damage, irreversible hearing loss), Nephrotoxicity Second-line injectable. Avoid in pregnancy (causes fetal congenital deafness).

Loading diagram... NTEP Diagnostic & Treatment Protocol for Pulmonary Tuberculosis